CN117098771A - 用于治疗阿尔茨海默病的组合物和方法 - Google Patents

用于治疗阿尔茨海默病的组合物和方法 Download PDF

Info

Publication number
CN117098771A
CN117098771A CN202180087609.5A CN202180087609A CN117098771A CN 117098771 A CN117098771 A CN 117098771A CN 202180087609 A CN202180087609 A CN 202180087609A CN 117098771 A CN117098771 A CN 117098771A
Authority
CN
China
Prior art keywords
gly
lys
ser
ala
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087609.5A
Other languages
English (en)
Chinese (zh)
Inventor
菱谷彰德
圭三古屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sola Biosciences Ltd
Original Assignee
Sola Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sola Biosciences Ltd filed Critical Sola Biosciences Ltd
Publication of CN117098771A publication Critical patent/CN117098771A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180087609.5A 2020-10-26 2021-10-26 用于治疗阿尔茨海默病的组合物和方法 Pending CN117098771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105472P 2020-10-26 2020-10-26
US63/105472 2020-10-26
PCT/US2021/056539 WO2022093736A1 (en) 2020-10-26 2021-10-26 Compositions and methods for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN117098771A true CN117098771A (zh) 2023-11-21

Family

ID=78676670

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180087609.5A Pending CN117098771A (zh) 2020-10-26 2021-10-26 用于治疗阿尔茨海默病的组合物和方法

Country Status (8)

Country Link
US (1) US20240025954A1 (https=)
EP (1) EP4232462A1 (https=)
JP (1) JP2023548632A (https=)
CN (1) CN117098771A (https=)
AU (1) AU2021367952A1 (https=)
CA (1) CA3199433A1 (https=)
TW (1) TW202233655A (https=)
WO (1) WO2022093736A1 (https=)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
JP2004502781A (ja) 2000-07-07 2004-01-29 パナシア　ファーマシューティカルズ　インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
PT2935326T (pt) * 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
US12162929B2 (en) 2018-02-19 2024-12-10 New York University Alpha-synuclein single domain antibodies
GB201902392D0 (en) * 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
EP4132955A2 (en) * 2020-04-10 2023-02-15 SOLA Biosciences LLC Compositions and methods for the treatment of protein aggregation disorders
BR112022021604A2 (pt) * 2020-04-28 2022-12-06 Sola Biosciences Llc Composições e métodos para tratamento de proteinopatias associadas à tdp-43

Also Published As

Publication number Publication date
AU2021367952A1 (en) 2023-06-08
JP2023548632A (ja) 2023-11-17
TW202233655A (zh) 2022-09-01
US20240025954A1 (en) 2024-01-25
CA3199433A1 (en) 2022-05-05
EP4232462A1 (en) 2023-08-30
WO2022093736A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
KR102121355B1 (ko) 변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법
US20240327477A1 (en) Compositions and methods for the treatment of tdp-43 proteinopathies
JP7285022B2 (ja) 組換えヒトＩＩ型ミトコンドリアダイニン様ＧＴＰａｓｅの遺伝子配列及びその使用
US20230234997A1 (en) Compositions and Methods for the Treatment of Synucleinopathies
US20230226223A1 (en) Compositions and Methods for the Treatment of Protein Aggregation Disorders
US20240400626A1 (en) Compositions and methods for the treatment of p53-mediated cancers
CN111926021A (zh) 重组人norrin胱氨酸结生长因子表达载体及其应用
CN117098771A (zh) 用于治疗阿尔茨海默病的组合物和方法
US20250042958A1 (en) Compositions and methods for the treatment of proteopathies
RU2855933C1 (ru) Композиции и способы для лечения протеинопатий tdp-43
RU2851326C1 (ru) Композиции и способы лечения нарушений агрегации белков
HK40092059A (zh) 用於治疗突触核蛋白病的组合物和方法
HK40088984A (zh) 用於治疗tdp-43蛋白病的组合物和方法
HK40087812A (zh) 用於治疗蛋白聚集障碍的组合物和方法
CN111909935A (zh) 重组人卷曲蛋白受体4（fzd4）的表达载体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination